ArticleJournal of managed care & specialty pharmacy2022
Cardiorenal disease in the United States: Future health care burden and potential impact of novel therapies.
Article in Journal of managed care & specialty pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Healthcare expenditures associated with cardiovascular, chronic kidney, and diabetic conditions, 2021-2023.BMC nephrology · 2026Article
- Temporal trends in heart failure and acute kidney injury-related mortality in the U.S.: a 21-year retrospective analysis of the CDC WONDER database.International urology and nephrology · 2025Article
- Trends and disparities in heart failure mortality with and without chronic kidney disease in a nationwide retrospective analysis.Scientific reports · 2025Article
- Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.Advances in therapy · 2024Article
- Humanistic and Economic Burden of Patients with Cardiorenal Metabolic Conditions: A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Review
- Estimation of glomerular filtration rate in cardiorenal patients: a step forward.Clinical kidney journal · 2023Article
- Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.Diabetes, obesity & metabolism · 2022Observational
- Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.